Intersect ENT

Intersect ENT was a medical device company based in Menlo Park, California that developed drug-eluting, bioresorbable sinus implants for patients with chronic rhinosinusitis. Its PROPEL family of steroid-eluting implants maintains sinus patency and delivers localized mometasone furoate to the sinus mucosa following endoscopic sinus surgery, while its SINUVA implant treats recurrent nasal polyps in an in-office setting. Formerly publicly traded on NASDAQ under the ticker XENT, Intersect ENT was acquired by Medtronic in May 2022 and its PROPEL and SINUVA product lines are now sold as part of Medtronic's ear, nose, and throat (ENT) portfolio. The company is a physical medical-device manufacturer and operates no public developer program, API, SDK, or documentation surface.

Intersect ENT is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Medical Devices, ENT, and Sinus Implants.

🌐 Visit website 📡 Source on GitHub

2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

Company Healthcare Medical DevicesENTSinus ImplantsDrug DeliveryMedtronic

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 2.2/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 0.0 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/intersect-ent: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Company 2

The organization behind the API

Website

Website

Website

Website

Other 1

Properties that don't map to a standard resource type

Acquirer

Acquirer

Source (apis.yml)

aid: intersect-ent
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/intersect-ent.png
name: Intersect ENT
description: Intersect ENT was a medical device company based in Menlo Park, California that developed drug-eluting, bioresorbable
  sinus implants for patients with chronic rhinosinusitis. Its PROPEL family of steroid-eluting implants maintains sinus patency
  and delivers localized mometasone furoate to the sinus mucosa following endoscopic sinus surgery, while its SINUVA implant
  treats recurrent nasal polyps in an in-office setting. Formerly publicly traded on NASDAQ under the ticker XENT, Intersect
  ENT was acquired by Medtronic in May 2022 and its PROPEL and SINUVA product lines are now sold as part of Medtronic's ear,
  nose, and throat (ENT) portfolio. The company is a physical medical-device manufacturer and operates no public developer
  program, API, SDK, or documentation surface.
url: https://raw.githubusercontent.com/api-evangelist/intersect-ent/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- kleiner-perkins
x-acquired-by: medtronic
x-acquired-date: '2022-05-13'
x-former-ticker: XENT
x-tier: stub
x-tier-reason: portfolio-lead
x-api-surface: none
x-enrichment-note: Physical medical-device company with no public API, developer portal, or documentation surface; own domain
  (intersectent.com) is defunct with an expired TLS certificate. Products now live on Medtronic ENT product pages. No API
  artifacts are derivable without fabrication.
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Healthcare
- Medical Devices
- ENT
- Sinus Implants
- Drug Delivery
- Medtronic
apis: []
common:
- type: Website
  url: https://www.medtronic.com/en-us/healthcare-professionals/products/ear-nose-throat/sinus-implants.html
  name: Medtronic ENT Sinus Implants (PROPEL / SINUVA)
- type: Website
  url: https://intersectent.com
- type: Acquirer
  url: https://news.medtronic.com/2022-05-13-Medtronic-completes-acquisition-of-Intersect-ENT
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence